Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Common Equity (2022 - 2025)

Historic Common Equity for Century Therapeutics (IPSC) over the last 4 years, with Q3 2025 value amounting to $176.3 million.

  • Century Therapeutics' Common Equity fell 988.22% to $176.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $176.3 million, marking a year-over-year decrease of 988.22%. This contributed to the annual value of $161.4 million for FY2024, which is 1265.93% down from last year.
  • Latest data reveals that Century Therapeutics reported Common Equity of $176.3 million as of Q3 2025, which was down 988.22% from $209.9 million recorded in Q2 2025.
  • In the past 5 years, Century Therapeutics' Common Equity ranged from a high of $386.7 million in Q1 2022 and a low of $161.4 million during Q4 2024
  • For the 4-year period, Century Therapeutics' Common Equity averaged around $246.0 million, with its median value being $222.1 million (2024).
  • In the last 5 years, Century Therapeutics' Common Equity tumbled by 3897.36% in 2023 and then surged by 3516.69% in 2025.
  • Quarter analysis of 4 years shows Century Therapeutics' Common Equity stood at $302.7 million in 2022, then plummeted by 38.97% to $184.8 million in 2023, then fell by 12.66% to $161.4 million in 2024, then grew by 9.29% to $176.3 million in 2025.
  • Its last three reported values are $176.3 million in Q3 2025, $209.9 million for Q2 2025, and $240.4 million during Q1 2025.